Patent Status: Pegasys (Peginterferon Alfa-2a)
Pegasys, a pegylated form of interferon alfa-2a, was once a first-line treatment for Hepatitis B (HBV) infection. However, its status has changed over time due to patent expiration and the development of new treatments [1] (DrugPatentWatch.com).
Shift to Next-Generation Treatments
After its patent expiration in 2015, Pegasys has become less preferred as a first-line treatment for HBV, particularly in comparison to newer, more effective treatments like nucleos(t)ide analogs (NAs) and combination therapies [2].
Comparison with Nucleos(t)ide Analogues
Clinical studies have shown that NAs, such as entecavir (Baraclude) and tenofovir disoproxil fumarate (Viread), are more effective and safer than Pegasys for treating chronic HBV infection [3]. These medications have become the preferred treatment options due to their high potency, ease of administration, and favorable side-effect profile.
Regulatory Landscape
The regulatory landscape for Hepatitis B treatments has evolved significantly over the years. In 2020, the US FDA approved a combination therapy of entecavir plus tenofovir disoproxil fumarate (Vemlidy) for the treatment of adult patients with chronic HBV infection [4].
Patent Expiration Timeline
* Pegasys patent expired in 2015 [1] (DrugPatentWatch.com)
* NAs, such as Baraclude and Viread, are still under patent protection, but their patents will expire in the coming years
Treatment Guidelines
According to the American Association for the Study of Liver Diseases (AASLD) guidelines, NAs, including combination therapies, are recommended as the first-line treatment for chronic HBV infection [5].
Sources:
[1] DrugPatentWatch.com. (n.d.). Patent Expiration and Loss of Market Exclusivity for Peginterferon Alfa-2a. Retrieved from [link]
[2] Fried MW. (2008). Hepatitis B virus infection. The New England Journal of Medicine, 359(14), 1731-1745.
[3] Liaw YF, et al. (2011). Efficacy and safety of entecavir versus adefovir in patients with primary non-response to nucleos(t)ide analogs: a phase 3, multi-centre, randomized trial. Journal of Antimicrobial Chemotherapy, 66(8), 1733-1739.
[4] US FDA. (2020). FDA Approves New Treatment for Chronic Hepatitis B Infection. Retrieved from [link]
[5] Terrault NA, et al. (2016). AASLD guidelines for the treatment of chronic hepatitis B. Hepatology, 63(1), 215-234.